Posturography in MS patients treated with high dose methylprednisolone.
Identifieur interne : 000669 ( Main/Exploration ); précédent : 000668; suivant : 000670Posturography in MS patients treated with high dose methylprednisolone.
Auteurs : Revital Gandelman-Marton [Israël] ; Aharon Arlazoroff [Israël] ; Zeevi Dvir [Israël]Source :
- Neurological research [ 1743-1328 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Femelle (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Injections veineuses (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Méthylprednisolone (usage thérapeutique), Neuroprotecteurs (usage thérapeutique), Posture (physiologie), Résultat thérapeutique (MeSH), Sclérose en plaques (complications), Sclérose en plaques (traitement médicamenteux), Statistique non paramétrique (MeSH), Troubles sensitifs (traitement médicamenteux), Troubles sensitifs (étiologie), Équilibre postural (effets des médicaments et des substances chimiques), Évaluation de l'invalidité (MeSH).
- MESH :
- effets des médicaments et des substances chimiques : Équilibre postural.
- physiologie : Posture.
- traitement médicamenteux : Sclérose en plaques, Troubles sensitifs.
- usage thérapeutique : Méthylprednisolone, Neuroprotecteurs, Sclérose en plaques.
- étiologie : Troubles sensitifs.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Indice de gravité de la maladie, Injections veineuses, Jeune adulte, Mâle, Résultat thérapeutique, Statistique non paramétrique, Évaluation de l'invalidité.
English descriptors
- KwdEn :
- Adult (MeSH), Disability Evaluation (MeSH), Female (MeSH), Humans (MeSH), Injections, Intravenous (MeSH), Male (MeSH), Methylprednisolone (therapeutic use), Middle Aged (MeSH), Multiple Sclerosis (complications), Multiple Sclerosis (drug therapy), Neuroprotective Agents (therapeutic use), Postural Balance (drug effects), Posture (physiology), Sensation Disorders (drug therapy), Sensation Disorders (etiology), Severity of Illness Index (MeSH), Statistics, Nonparametric (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Methylprednisolone, Neuroprotective Agents.
- complications : Multiple Sclerosis.
- drug effects : Postural Balance.
- drug therapy : Multiple Sclerosis, Sensation Disorders.
- etiology : Sensation Disorders.
- physiology : Posture.
- Adult, Disability Evaluation, Female, Humans, Injections, Intravenous, Male, Middle Aged, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome, Young Adult.
Abstract
OBJECTIVES
To evaluate the sensitivity of the balance sway index (SI) to drug-induced functional changes during acute relapse in patients with MS.
METHODS
Dynamic posturography was used to derive the SI in 11 healthy subjects and 13 MS patients before and after intravenous high dose methylprednisolone (HDMP).
RESULTS
In both groups, SI was lower in the least demanding task and increased with test complexity. Compared to the healthy group, patients were distinguished by a higher SI both prior to and following administration of HDMP (p < 0.008). However, the effect of the drug on patients' SI was unremarkable. Total Expanded Disability Status Scale score was lower after treatment compared to pre-treatment values (p < 0.001), with significantly lower mean score recorded in patients with pyramidal and cerebellar abnormalities (p = 0.017 and p = 0.011, respectively).
DISCUSSION
The SI measure of dynamic posturography is not sensitive to short-term HDMP-induced functional changes during acute relapse in patients with MS. Further studies are needed to evaluate modified balance protocols and the possible long-term treatment effects of HDMP on SI.
DOI: 10.1080/01616412.2016.1177927
PubMed: 27151095
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Posturography in MS patients treated with high dose methylprednisolone.</title><author><name sortKey="Gandelman Marton, Revital" sort="Gandelman Marton, Revital" uniqKey="Gandelman Marton R" first="Revital" last="Gandelman-Marton">Revital Gandelman-Marton</name><affiliation wicri:level="1"><nlm:affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin </wicri:regionArea><wicri:noRegion>Zerifin </wicri:noRegion></affiliation></author><author><name sortKey="Arlazoroff, Aharon" sort="Arlazoroff, Aharon" uniqKey="Arlazoroff A" first="Aharon" last="Arlazoroff">Aharon Arlazoroff</name><affiliation wicri:level="1"><nlm:affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin </wicri:regionArea><wicri:noRegion>Zerifin </wicri:noRegion></affiliation></author><author><name sortKey="Dvir, Zeevi" sort="Dvir, Zeevi" uniqKey="Dvir Z" first="Zeevi" last="Dvir">Zeevi Dvir</name><affiliation wicri:level="1"><nlm:affiliation>b The Sackler Faculty of Medicine, Department of Physical Therapy , Tel Aviv University , Tel Aviv , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>b The Sackler Faculty of Medicine, Department of Physical Therapy , Tel Aviv University , Tel Aviv </wicri:regionArea><wicri:noRegion>Tel Aviv </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27151095</idno><idno type="pmid">27151095</idno><idno type="doi">10.1080/01616412.2016.1177927</idno><idno type="wicri:Area/Main/Corpus">000675</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000675</idno><idno type="wicri:Area/Main/Curation">000675</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000675</idno><idno type="wicri:Area/Main/Exploration">000675</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Posturography in MS patients treated with high dose methylprednisolone.</title><author><name sortKey="Gandelman Marton, Revital" sort="Gandelman Marton, Revital" uniqKey="Gandelman Marton R" first="Revital" last="Gandelman-Marton">Revital Gandelman-Marton</name><affiliation wicri:level="1"><nlm:affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin </wicri:regionArea><wicri:noRegion>Zerifin </wicri:noRegion></affiliation></author><author><name sortKey="Arlazoroff, Aharon" sort="Arlazoroff, Aharon" uniqKey="Arlazoroff A" first="Aharon" last="Arlazoroff">Aharon Arlazoroff</name><affiliation wicri:level="1"><nlm:affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin </wicri:regionArea><wicri:noRegion>Zerifin </wicri:noRegion></affiliation></author><author><name sortKey="Dvir, Zeevi" sort="Dvir, Zeevi" uniqKey="Dvir Z" first="Zeevi" last="Dvir">Zeevi Dvir</name><affiliation wicri:level="1"><nlm:affiliation>b The Sackler Faculty of Medicine, Department of Physical Therapy , Tel Aviv University , Tel Aviv , Israel.</nlm:affiliation><country xml:lang="fr">Israël</country><wicri:regionArea>b The Sackler Faculty of Medicine, Department of Physical Therapy , Tel Aviv University , Tel Aviv </wicri:regionArea><wicri:noRegion>Tel Aviv </wicri:noRegion></affiliation></author></analytic><series><title level="j">Neurological research</title><idno type="eISSN">1743-1328</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Disability Evaluation (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Injections, Intravenous (MeSH)</term><term>Male (MeSH)</term><term>Methylprednisolone (therapeutic use)</term><term>Middle Aged (MeSH)</term><term>Multiple Sclerosis (complications)</term><term>Multiple Sclerosis (drug therapy)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Postural Balance (drug effects)</term><term>Posture (physiology)</term><term>Sensation Disorders (drug therapy)</term><term>Sensation Disorders (etiology)</term><term>Severity of Illness Index (MeSH)</term><term>Statistics, Nonparametric (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Indice de gravité de la maladie (MeSH)</term><term>Injections veineuses (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Méthylprednisolone (usage thérapeutique)</term><term>Neuroprotecteurs (usage thérapeutique)</term><term>Posture (physiologie)</term><term>Résultat thérapeutique (MeSH)</term><term>Sclérose en plaques (complications)</term><term>Sclérose en plaques (traitement médicamenteux)</term><term>Statistique non paramétrique (MeSH)</term><term>Troubles sensitifs (traitement médicamenteux)</term><term>Troubles sensitifs (étiologie)</term><term>Équilibre postural (effets des médicaments et des substances chimiques)</term><term>Évaluation de l'invalidité (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Methylprednisolone</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Multiple Sclerosis</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Postural Balance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Sclerosis</term><term>Sensation Disorders</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Équilibre postural</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Sensation Disorders</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Posture</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Posture</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sclérose en plaques</term><term>Troubles sensitifs</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Méthylprednisolone</term><term>Neuroprotecteurs</term><term>Sclérose en plaques</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Troubles sensitifs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Disability Evaluation</term><term>Female</term><term>Humans</term><term>Injections, Intravenous</term><term>Male</term><term>Middle Aged</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Indice de gravité de la maladie</term><term>Injections veineuses</term><term>Jeune adulte</term><term>Mâle</term><term>Résultat thérapeutique</term><term>Statistique non paramétrique</term><term>Évaluation de l'invalidité</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To evaluate the sensitivity of the balance sway index (SI) to drug-induced functional changes during acute relapse in patients with MS.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Dynamic posturography was used to derive the SI in 11 healthy subjects and 13 MS patients before and after intravenous high dose methylprednisolone (HDMP).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>In both groups, SI was lower in the least demanding task and increased with test complexity. Compared to the healthy group, patients were distinguished by a higher SI both prior to and following administration of HDMP (p < 0.008). However, the effect of the drug on patients' SI was unremarkable. Total Expanded Disability Status Scale score was lower after treatment compared to pre-treatment values (p < 0.001), with significantly lower mean score recorded in patients with pyramidal and cerebellar abnormalities (p = 0.017 and p = 0.011, respectively).</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>The SI measure of dynamic posturography is not sensitive to short-term HDMP-induced functional changes during acute relapse in patients with MS. Further studies are needed to evaluate modified balance protocols and the possible long-term treatment effects of HDMP on SI.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27151095</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1743-1328</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurological research</Title><ISOAbbreviation>Neurol Res</ISOAbbreviation></Journal><ArticleTitle>Posturography in MS patients treated with high dose methylprednisolone.</ArticleTitle><Pagination><MedlinePgn>570-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/01616412.2016.1177927</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To evaluate the sensitivity of the balance sway index (SI) to drug-induced functional changes during acute relapse in patients with MS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Dynamic posturography was used to derive the SI in 11 healthy subjects and 13 MS patients before and after intravenous high dose methylprednisolone (HDMP).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In both groups, SI was lower in the least demanding task and increased with test complexity. Compared to the healthy group, patients were distinguished by a higher SI both prior to and following administration of HDMP (p < 0.008). However, the effect of the drug on patients' SI was unremarkable. Total Expanded Disability Status Scale score was lower after treatment compared to pre-treatment values (p < 0.001), with significantly lower mean score recorded in patients with pyramidal and cerebellar abnormalities (p = 0.017 and p = 0.011, respectively).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The SI measure of dynamic posturography is not sensitive to short-term HDMP-induced functional changes during acute relapse in patients with MS. Further studies are needed to evaluate modified balance protocols and the possible long-term treatment effects of HDMP on SI.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gandelman-Marton</LastName><ForeName>Revital</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arlazoroff</LastName><ForeName>Aharon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Department of Neurology , Assaf Harofeh Medical Center , Zerifin , Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvir</LastName><ForeName>Zeevi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>b The Sackler Faculty of Medicine, Department of Physical Therapy , Tel Aviv University , Tel Aviv , Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurol Res</MedlineTA><NlmUniqueID>7905298</NlmUniqueID><ISSNLinking>0161-6412</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>X4W7ZR7023</RegistryNumber><NameOfSubstance UI="D008775">Methylprednisolone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007275" MajorTopicYN="N">Injections, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008775" MajorTopicYN="N">Methylprednisolone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004856" MajorTopicYN="N">Postural Balance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011187" MajorTopicYN="N">Posture</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012678" MajorTopicYN="N">Sensation Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Methylprednisolone</Keyword><Keyword MajorTopicYN="N">Multiple sclerosis</Keyword><Keyword MajorTopicYN="N">Postural control</Keyword><Keyword MajorTopicYN="N">Posturography</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27151095</ArticleId><ArticleId IdType="doi">10.1080/01616412.2016.1177927</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Gandelman Marton, Revital" sort="Gandelman Marton, Revital" uniqKey="Gandelman Marton R" first="Revital" last="Gandelman-Marton">Revital Gandelman-Marton</name></noRegion><name sortKey="Arlazoroff, Aharon" sort="Arlazoroff, Aharon" uniqKey="Arlazoroff A" first="Aharon" last="Arlazoroff">Aharon Arlazoroff</name><name sortKey="Dvir, Zeevi" sort="Dvir, Zeevi" uniqKey="Dvir Z" first="Zeevi" last="Dvir">Zeevi Dvir</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PosturoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000669 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000669 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PosturoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27151095
|texte= Posturography in MS patients treated with high dose methylprednisolone.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27151095" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PosturoV1
| This area was generated with Dilib version V0.6.37. |  |